Shandong Xinhua Pharmaceutical erhält Zulassung für Glucosamin-Sulfat-Kapseln in China
I'm PortAI, I can summarize articles.
Shandong Xinhua Pharmaceutical Company Ltd. has received regulatory approval for Glucosamine Sulfate capsules in China. The approval was granted under the Drug Administration Law of the People's Republic of China after review. The product is classified as an over-the-counter medication of category A. Production and sales can only commence after compliance with applicable pharmaceutical manufacturing standards. No other organizations are mentioned in the announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments